BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment
GIOSTAR COVID19 - Positive Outcome

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

July 28, 2020 By Cade Hildreth (CEO) Leave a Comment

Promising results point to a potential alternative in combating the pandemic

San Diego, July 28, 2020 — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program. As of July 14, 2020, there have been more than 13 million COVID-19 cases and over 500,000 deaths worldwide.

Contending with a Grim Prognosis

GIOSTAR COVID19
GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program.

Under the direction of GIOSTAR Medical Director Dr. Prabhat Soni, a 53-year old male patient suffering from COVID-19 pneumonia was admitted to Saint Michael’s Medical Center in Newark, New Jersey, under the care of Dr. Richard Miller, MD, Chairman, Department of Pulmonary Medicine. The patient’s condition worsened over the course of the standard treatments, along with convalescent plasma therapy. He went into septic shock and his renal and hepatic functions continued to decline, requiring dialysis. The patient suffered a stroke, and remained in a coma at Saint Michael’s intensive care unit (ICU).

Improved Outcomes from an Alternative Strategy

Noting the limited effectiveness of these measures, Dr. Soni designed a plan to treat the patient using stem cells. Research physician Dr. Michael J. DeMarco coordinated the plan, with day-to-day care provided to the patient by Dr. Miller and his Critical Care fellows Dr. Rutwik Patel and Dr. Harish Sharma, at Saint Michael’s.

Following treatment with AlloRx Stem Cells® from Vitro Biopharma, a Colorado-based company, the patient began recovery from multiple organ failure and a coma of almost 7 weeks.  He had excellent recovery of his pulmonary, liver, and renal functions, ultimately coming off dialysis and ventilator support.

The patient’s recovery of neuromuscular functions is evident in improved clarity of speech, ease of swallowing food, and many other everyday functions. Additionally, the elevated levels of inflammation markers seen prior to stem cell therapy have come down to within normal range. The patient was finally discharged from ICU, and is undergoing physical therapy with strong hopes of complete recovery.

Pluristyx

COVID-19 and Mesenchymal Stem Cells (MSCs)

COVID-19 infection leads to uncontrolled release of proinflammatory cytokines – known as “cytokine storms” – that potentially leads to fatal damage of many organs of the body. “MSCs have specific characteristics that, when infused in the bloodstream,” explained Dr. Srivastava, “neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.”

Next Steps for Treatment of COVID-19

“We got outstanding results after using MSCs on our first patient,” noted Dr. Soni, “with similar results being reported by other institutions.” Dr. Srivastava states that “the use of MSCs may be a great option not only for critically ill COVID-19 patients, but also for those who may have risk of exposure. MSCs may prevent people from aggravations of the infection, thereby potentially saving lives while lowering the load on hospitals and the economy.” Drs. Srivastava and Soni emphasize that a placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of stem cell research. Under the leadership of Co-Founders Dr. Anand Srivastava and Mr. Deven Patel, the San Diego-based Institute has a tradition of groundbreaking research in stem cell science spanning over two decades.

Media Contact
Deven Patel
244294@email4pr.com

Related Links
https://www.giostar.com/2020/07/20/giostar-reports-positive-outcome-covid-19-patient-stem-cell-treatment/

https://giostarchicago.com/news/

SOURCE: GIOSTAR

5/5 - (2 votes)

Filed Under: Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: COVID-19, GIOSTAR

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.